DNA mismatch repair and the transition to hormone independence in breast and prostate cancer

Cancer Letters

Volumn 291, Issue 2, 2010, Pages 142-149

  Martin, Lynn ^a,b   Coffey, Mary ^a   Lawler, Mark ^b   Hollywood, Donal ^a,b   Marignol, Laure ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Academic Unit of Clinical and Molecular Oncology   (Ireland)

Author keywords

Breast cancer; Hormone independence; Mismatch repair; MSH2; Prostate cancer

Indexed keywords

HORMONE RECEPTOR; MISMATCH REPAIR PROTEIN; PROTEIN MSH2;

BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENE MUTATION; GENOMIC INSTABILITY; HORMONE DEPENDENCE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 77950300607     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.10.007     Document Type: Review

References (94)

1. Hortobagyi G.N., de la Garza Salazar J., Pritchard K., Amadori D., Haidinger R., Hudis C.A., Khaled H., Liu M.C., Martin M., Namer M., O'Shaughnessy J.A., Shen Z.Z., and Albain K.S. The global breast cancer burden: variations in epidemiology and survival. Clin. Breast Cancer 6 (2005) 391-401
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics 2009. CA Cancer J. Clin. 59 (2009) 225-249
3. Henderson B.E., and Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 21 (2000) 427-433
4. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J. Urol. 168 (2002) 9-12
5. Laufer M., Denmeade S.R., Sinibaldi V.J., Carducci M.A., and Eisenberger M.A. Complete androgen blockade for prostate cancer: what went wrong?. J. Urol. 164 (2000) 3-9
6. Johnston S.R. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drug 8 (1997) 911-930
7. A.M. Ferreira, H. Westers, A. Albergaria, R. Seruca, R.M. Hofstra, Estrogens, MSI and Lynch syndrome-associated tumors, Biochim. Biophys. Acta (2009).
8. Ricke W.A., Ishii K., Ricke E.A., Simko J., Wang Y., Hayward S.W., and Cunha G.R. Steroid hormones stimulate human prostate cancer progression and metastasis. Int. J. Cancer 118 (2006) 2123-2131
9. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell Biochem. 253 (2003) 89-101
10. Karan D., Schmied B.M., Dave B.J., Wittel U.A., Lin M.F., and Batra S.K. Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin. Cancer Res. 7 (2001) 3472-8340
11. Roddam A.W., Allen N.E., Appleby P., and Key T.J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl. Cancer Inst. 100 (2008) 170-183
12. Chatterjee S.K., and Zetter B.R. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 1 (2005) 37-50
13. Ludwig J.A., and Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5 (2005) 845-856
14. Hawn M.T., Umar A., Carethers J.M., Marra G., Kunkel T.A., Boland C.R., and Koi M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55 (1995) 3721-3725
15. Gibson S.L., Narayanan L., Hegan D.C., Buermeyer A.B., Liskay R.M., and Glazer P.M. Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett. 244 (2006) 195-202
16. Li G.M. Mechanisms and functions of DNA mismatch repair. Cell Res. 18 (2008) 85-98
17. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin. Oncol. 21 (2003) 1174-1179
18. Iyer R.R., Pluciennik A., Burdett V., and Modrich P.L. DNA mismatch repair: functions and mechanisms. Chem. Rev. 106 (2006) 302-323
19. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7 (2006) 335-346
20. Franchitto A., Pichierri P., Piergentili R., Crescenzi M., Bignami M., and Palitti F. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene 22 (2003) 2110-2120
21. Kobayashi K., Karran P., Oda S., and Yanaga K. Involvement of mismatch repair in transcription-coupled nucleotide excision repair. Hum. Cell 18 (2005) 103-115
22. Davis T.W., Wilson-Van Patten C., Meyers M., Kunugi K.A., Cuthill S., Reznikoff C., Garces C., Boland C.R., Kinsella T.J., Fishel R., and Boothman D.A. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res. 58 (1998) 767-778
23. Cejka P., Stojic L., Mojas N., Russell A.M., Heinimann K., Cannavo E., di Pietro M., Marra G., and Jiricny J. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. Embo. J. 22 (2003) 2245-2254
24. Hirose Y., Katayama M., Stokoe D., Haas-Kogan D.A., Berger M.S., and Pieper R.O. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol. Cell Biol. 23 (2003) 8306-8315
25. Yeh C.C., Lee C., and Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem. Biophys. Res. Commun. 285 (2001) 409-413
26. Mohd A.B., Palama B., Nelson S.E., Tomer G., Nguyen M., Huo X., and Buermeyer A.B. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair. DNA Repair (Amst) 5 (2006) 347-361
27. Chintamani, Jha B.P., Bhandari V., Bansal A., Saxena S., and Bhatnagar D. The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int. Semin. Surg. Oncol. 4 (2007) 5
28. Koster F., Schroer A., Fischer D., Horn A.K., Diedrich K., and Friedrich M. Immunohistochemistry of proteins for DNA mismatch repair in correlation to prognostic factors of mammarian cancer. Oncol. Rep. 17 (2007) 1223-1227
29. Jenkins M.A., Baglietto L., Dowty J.G., Van Vliet C.M., Smith L., Mead L.J., Macrae F.A., St John D.J., Jass J.R., Giles G.G., Hopper J.L., and Southey M.C. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin. Gastroenterol. Hepatol. 4 (2006) 489-498
30. Vasen H.F., Watson P., Mecklin J.P., and Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
31. Schafmayer C., Buch S., Egberts J.H., Franke A., Brosch M., El Sharawy A., Conring M., Koschnick M., Schwiedernoch S., Katalinic A., Kremer B., Folsch U.R., Krawczak M., Fandrich F., Schreiber S., Tepel J., and Hampe J. Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer. Int. J. Cancer 121 (2007) 555-558
32. Takano K., Ichikawa Y., Ueno E., Ohwada M., Suzuki M., Tsunoda H., Miwa M., Uchida K., and Yoshikawa H. Microsatellite instability and expression of mismatch repair genes in sporadic endometrial cancer coexisting with colorectal or breast cancer. Oncol. Rep. 13 (2005) 11-16
33. Bianchi F., Rosati S., Belvederesi L., Loretelli C., Catalani R., Mandolesi A., Bracci R., Bearzi I., Porfiri E., and Cellerino R. MSH2 splice site mutation and endometrial cancer. Int. J. Gynecol. Cancer 16 (2006) 1419-1423
34. Kanemitsu K., Kawasaki K., Nakamura M., Li D., Yasuda T., Kuroda D., Yokozaki H., Kamigaki T., and Kuroda Y. MSI is frequently recognized among gastric cancer patients with a family history of cancer. Hepatogastroenterology 54 (2007) 2410-2414
35. Yamamoto M., Taguchi K., Baba H., Endo K., Kohnoe S., Okamura T., and Maehara Y. Loss of protein expression of hMLH1 and hMSH2 with double primary carcinomas of the stomach and colorectum. Oncol. Rep. 16 (2006) 41-47
36. Nunn J., Nagini S., Risk J.M., Prime W., Maloney P., Liloglou T., Jones A.S., Rogers S.R., Gosney J.R., Woolgar J., and Field J.K. Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3 in squamous cell carcinoma of the head and neck. Oral Oncol. 39 (2003) 115-129
37. Nijhuis E.R., Nijman H.W., Oien K.A., Bell A., Ten Hoor K.A., Reesink-Peters N., Boezen H.M., Hollema H., and van der Zee A.G. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J. Clin. Pathol. 60 (2007) 824-830
38. Chen Y., Wang J., Fraig M.M., Henderson K., Bissada N.K., Watson D.K., and Schweinfest C.W. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int. J. Oncol. 22 (2003) 1033-1043
39. Murata H., Khattar N.H., Gu L., and Li G.M. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 223 (2005) 143-150
40. Wheeler J.M., Bodmer W.F., and Mortensen N.J. DNA mismatch repair genes and colorectal cancer. Gut 47 (2000) 148-153
41. Siah S.P., Quinn D.M., Bennett G.D., Casey G., Flower R.L., Suthers G., and Rudzki Z. Microsatellite instability markers in breast cancer: a review and study showing MSI was not detected at 'BAT 25' and 'BAT 26' microsatellite markers in early-onset breast cancer. Breast Cancer Res. Treat 60 (2000) 135-142
42. Caldes T., Perez-Segura P., Tosar A., De La Hoya M., and Diaz-Rubio E. Low frequency of microsatellite instability in sporadic breast cancer. Int. J. Oncol. 16 (2000) 1235-1242
43. Anbazhagan R., Fujii H., and Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin. Cancer Res. 5 (1999) 839-844
44. Lee S.C., Berg K.D., Sherman M.E., Griffin C.A., and Eshleman J.R. Microsatellite instability is infrequent in medullary breast cancer. Am. J. Clin. Pathol. 115 (2001) 823-827
45. Imyanitov E.N., Togo A.V., Suspitsin E.N., Grigoriev M.Y., Pozharisski K.M., Turkevich E.A., Hanson K.P., Hayward N.K., Chenevix-Trench G., Theillet C., and Lavin M.F. Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett. 154 (2000) 9-17
46. Toyama T., Iwase H., Iwata H., Hara Y., Omoto Y., Suchi M., Kato T., Nakamura T., and Kobayashi S. Microsatellite instability in in situ and invasive sporadic breast cancers of Japanese women. Cancer Lett. 108 (1996) 205-209
47. Rosenberg C.L., Larson P.S., Romo J.D., De Las Morenas A., and Faller D.V. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum. Pathol. 28 (1997) 214-219
48. Huang Y., Bove B., Wu Y., Russo I.H., Yang X., Zekri A., and Russo J. Microsatellite instability during the immortalization and transformation of human breast epithelial cells in vitro. Mol. Carcinogen. 24 (1999) 118-127
49. Shen K.L., Yang L.S., Hsieh H.F., Chen C.J., Yu J.C., Tsai N.M., and Harn H.J. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor) and PR (progesterone receptor) protein immunoreactivity. J. Surg. Oncol. 74 (2000) 100-107
50. Ellsworth R.E., Ellsworth D.L., Love B., Patney H.L., Hoffman L.R., Kane J., Hooke J.A., and Shriver C.D. Correlation of levels and patterns of genomic instability with histological grading of DCIS. Ann. Surg. Oncol. 14 (2007) 3070-3077
51. Azzouzi A.R., Catto J.W., Rehman I., Larre S., Roupret M., Feeley K.M., Cussenot O., Meuth M., and Hamdy F.C. Clinically localised prostate cancer is microsatellite stable. BJU Int. 99 (2007) 1031-1035
52. Dahiya R., Lee C., McCarville J., Hu W., Kaur G., and Deng G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int. J. Cancer 72 (1997) 762-767
53. Perinchery G., Nojima D., Goharderakhshan R., Tanaka Y., Alonzo J., and Dahiya R. Microsatellite instability of dinucleotide tandem repeat sequences is higher than trinucleotide, tetranucleotide and pentanucleotide repeat sequences in prostate cancer. Int. J. Oncol. 16 (2000) 1203-1209
54. Watanabe M., Imai H., Kato H., Shiraishi T., Ushijima T., Nagao M., and Yatani R. Microsatellite instability in latent prostate cancers. Int. J. Cancer 69 (1996) 394-397
55. Ahman A.K., Jonsson B.A., Damber J.E., Bergh A., and Gronberg H. Low frequency of microsatellite instability in hereditary prostate cancer. BJU Int. 87 (2001) 334-338
56. Velasco A., Hewitt S.M., Albert P.S., Hossein M., Rosenberg H., Martinez C., Sagalowsky A.I., McConnell J.D., Marston W., and Leach F.S. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 94 (2002) 690-699
57. Brennetot C., Buhard O., Jourdan F., Flejou J.F., Duval A., and Hamelin R. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening. Int. J. Cancer 113 (2005) 446-450
58. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J. Mol. Diagn. 10 (2008) 293-300
59. Baudhuin L.M., Burgart L.J., Leontovich O., and Thibodeau S.N. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam. Cancer 4 (2005) 255-265
60. Shia J., Klimstra D.S., Nafa K., Offit K., Guillem J.G., Markowitz A.J., Gerald W.L., and Ellis N.A. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am. J. Surg. Pathol. 29 (2005) 96-104
61. Lindor N.M., Petersen G.M., Hadley D.W., Kinney A.Y., Miesfeldt S., Lu K.H., Lynch P., Burke W., and Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296 (2006) 1507-1517
62. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part II. The utility of microsatellite instability testing. J. Mol. Diagn. 10 (2008) 301-307
63. Naqvi R.A., Hussain A., Deo S.S., Kukreti H., Chauhan M., Sarin R., Saxena A., Asim M., Shukla N.K., Husain S.A., Pasha S.T., and Basir S.F. Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women. Hum. Pathol. 39 (2008) 672-680
64. Smith T.R., Levine E.A., Freimanis R.I., Akman S.A., Allen G.O., Hoang K.N., Liu-Mares W., and Hu J.J. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis 29 (2008) 2132-2138
65. Chen Y., Wang J., Fraig M.M., Metcalf J., Turner W.R., Bissada N.K., Watson D.K., and Schweinfest C.W. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 61 (2001) 4112-4121
66. Burger M., Denzinger S., Hammerschmied C.G., Tannapfel A., Obermann E.C., Wieland W.F., Hartmann A., and Stoehr R. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J. Mol. Med. 84 (2006) 833-841
67. Strom S.S., Spitz M.R., Yamamura Y., Babaian R.J., Scardino P.T., and Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 47 (2001) 269-275
68. Chuang S.T., Adley B., Han M., Lin F., Yang X.J., and Catalona W.J. Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer. Histopathology 52 (2008) 247-2450
69. Murata H., Khattar N.H., Kang Y., Gu L., and Li G.M. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene 21 (2002) 5696-5703
70. Ollikainen M., Hannelius U., Lindgren C.M., Abdel-Rahman W.M., Kere J., and Peltomaki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach. Oncogene 26 (2007) 4541-4549
71. Raptis S., Mrkonjic M., Green R.C., Pethe V.V., Monga N., Chan Y.M., Daftary D., Dicks E., Younghusband B.H., Parfrey P.S., Gallinger S.S., McLaughlin J.R., Knight J.A., and Bapat B. MLH1-93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J. Natl. Cancer Inst. 99 (2007) 463-474
72. Leach F.S., Velasco A., Hsieh J.T., Sagalowsky A.I., and McConnell J.D. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP. J. Urol. 164 (2000) 1830-1833
73. Martin L., Marples B., Coffey M., Lawler M., Hollywood D., and Marignol L. Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity. Radiat. Res. 172 (2009) 405-413
74. Prtilo A., Leach F.S., Markwalder R., Kappeler A., Burkhard F.C., Cecchini M.G., Studer U.E., and Thalmann G.N. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J. Urol. 174 (2005) 1814-1818 (discussion 1818)
75. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., and Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 10 (2004) 20-26
76. Casorelli I., Russo M.T., and Bignami M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agent Med. Chem. 8 (2008) 368-380
77. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 8 (2001) 1076-1092
78. Benachenhou N., Guiral S., Gorska-Flipot I., Labuda D., and Sinnett D. Frequent loss of heterozygosity at the DNA mismatch-repair loci hMLH1 and hMSH3 in sporadic breast cancer. Br. J. Cancer 79 (1999) 1012-1017
79. Hirata H., Hinoda Y., Kawamoto K., Kikuno N., Suehiro Y., Okayama N., Tanaka Y., and Dahiya R. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J. Urol. 179 (2008) 2020-2024
80. Balogh G.A., Russo I.H., and Russo J. Truncation of the mismatch repair protein PMS2 during the neoplastic transformation of human breast epithelial cells in vitro. Int. J. Oncol. 25 (2004) 381-387
81. Norris A.M., Woodruff R.D., D'Agostino Jr. R.B., Clodfelter J.E., and Scarpinato K.D. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 67 (2007) 214-225
82. Marra G., Chang C.L., Laghi L.A., Chauhan D.P., Young D., and Boland C.R. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 13 (1996) 2189-2196
83. Miyamoto T., Shiozawa T., Kashima H., Feng Y.Z., Suzuki A., Kurai M., Nikaido T., and Konishi I. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology 147 (2006) 4863-4870
84. Wada-Hiraike O., Yano T., Nei T., Matsumoto Y., Nagasaka K., Takizawa S., Oishi H., Arimoto T., Nakagawa S., Yasugi T., Kato S., and Taketani Y. The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br. J. Cancer 92 (2005) 2286-2291
85. Norris A.M., Gentry M., Peehl D.M., D'Agostino Jr. R., and Scarpinato K.D. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol. Biomarkers. Prev. 18 (2009) 57-64
86. Karihtala P., Winqvist R., Syvaoja J.E., Kinnula V.L., and Soini Y. Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur. J. Cancer 42 (2006) 2653-2659
87. Bock N., Meden H., Regenbrecht M., Junemann B., Wangerin J., and Marx D. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast. Anticancer Res. 20 (2000) 119-124
88. Fromont G., Chene L., Vidaud M., Vallancien G., Mangin P., Fournier G., Validire P., Latil A., and Cussenot O. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int. J. Cancer 114 (2005) 174-181
89. Caldes T., Perez-Segura P., Tosar A., de La Hoya M., and Diaz-Rubio E. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. Teratogen. Carcinogen. Mutagen. 20 (2000) 283-291
90. Shaw J.A., Walsh T., Chappell S.A., Carey N., Johnson K., and Walker R.A. Microsatellite instability in early sporadic breast cancer. Br. J. Cancer 73 (1996) 1393-1397
91. Velasco A., Albert P.S., Rosenberg H., Martinez C., and Leach F.S. Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol. Ther. 1 (2002) 362-367
92. Balogh G.A., Heulings R.C., and Russo J. The mismatch repair gene hPMS2 is mutated in primary breast cancer. Int. J. Mol. Med. 18 (2006) 853-857
93. Khilko N., Bourne P., Qi Y., and Ping T. Mismatch repair genes hMLH1 and hMSH2 may not play an essential role in breast carcinogenesis. Int. J. Surg. Pathol. 15 (2007) 233-241
94. Wong E.M., Tesoriero A.A., Pupo G.M., McCredie M.R., Giles G.G., Hopper J.L., Mann G.J., Goldgar D.E., and Southey M.C. Is MSH2 a breast cancer susceptibility gene?. Fam. Cancer 7 (2008) 151-155